利用增强MDCT和FSE T2加权MRI评估透明细胞型和乳头状肾细胞癌的肿瘤分级:影像-病理对照研究
回顾性评估66例肾细胞癌患者(52例透明细胞型、14例乳头状型),分析皮髓质期增强MDCT的平均衰减值和FSE T2加权MRI的平均信号强度值与WHO/国际泌尿病理学会分级的关系。两种亚型肿瘤的皮髓质期CT衰减值均与分级呈正相关(p<0.001);透明细胞型T2信号强度与分级相关(p<0.001),但两亚型合并分析时T2信号与分级无统计学显著相关(p>0.05)。
要点
- 皮髓质期增强CT上,高分级肾细胞癌平均衰减值高于低分级(74.3±22.3 HU vs 55.2±23.7 HU),两亚型均呈正相关(p<0.001)。
- 透明细胞型肾细胞癌低分级者T2加权信号强度高于高分级者(475.7±51.3 vs 418.5±45.7),相关有统计学意义(p<0.001)。
- 两亚型合并分析时T2加权信号强度与分级无统计学显著相关(p>0.05),低分级408.9±44.6 vs 高分级382.1±44.2。
核心结论
- 增强MDCT和T2加权FSE MRI可能在区分两种亚型肾细胞癌的低分级与高分级肿瘤中发挥重要作用,这些无创评估技术可能对患者管理和治疗策略的确定产生积极影响。
研究设计与样本
- 回顾性研究,纳入66例经组织病理学证实并接受部分或全肾切除术的肾细胞癌患者,其中透明细胞型52例、乳头状型14例,男性50例(76%)、女性16例(24%)。
关键影像表现/征象
- 皮髓质期增强CT上高分级肿瘤平均衰减值74.3±22.3 HU,高于低分级肿瘤55.2±23.7 HU,两亚型均呈正相关(p<0.001)。
- FSE T2加权MRI上低分级肿瘤平均信号强度408.9±44.6,高分级肿瘤382.1±44.2,两亚型合并分析与分级无统计学显著相关(p>0.05)。
- 透明细胞型亚组中低分级(1-2级)平均信号强度475.7±51.3,高于高分级(3-4级)418.5±45.7,相关有统计学意义(p<0.001)。
- 乳头状型亚组中高分级肿瘤皮髓质期CT平均衰减值54.2±25.2,高于低分级35.5±18.8,相关有统计学意义(p<0.001)。
诊断标准与关键数值
- 分级标准采用WHO/国际泌尿病理学会分级系统,将肿瘤分为低分级(1-2级)和高分级(3-4级)。
- CT衰减值在皮髓质期增强MDCT图像上以HU为单位测量,采用感兴趣区和包括正常肾皮质在内的全病灶测量法。
- T2信号强度在FSE T2加权MR图像上测量,同样采用感兴趣区和全病灶测量法。
临床应用与阅片要点
- 阅片时可关注皮髓质期增强CT的平均衰减值,高分级肾细胞癌倾向于表现为更高的衰减值(两亚型均呈正相关)。
- 在透明细胞型肾细胞癌中,T2加权信号强度较低可能提示高分级,但该关联在乳头状型中未得到证实。
- 两亚型合并分析时T2信号强度与分级无统计学显著相关,评估T2信号时需结合肿瘤亚型分别判读。
局限性
- 本研究为回顾性评估。
- 部分患者仅接受CT或仅接受MRI检查,并非所有患者均完成两种检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Discrimination of low grade (grade 1-2) renal tumors from high grade (grade 3-4) ones carries crucial importance in terms of the management of these patients and also in the decision-making of appropriate treatment strategies. Our aim was to investigate whether contrast-enhanced multidetector computed tomography (MDCT) and T2 weighted fast spin echo (FSE) magnetic resonance imaging (MRI) could play a specific role in the discrimination of low grade versus high grade tumors in clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) patients.
METHODS: In this study, we retrospectively evaluated 66 RCC patients based on histopathologic findings who had underwent either partial or total nephrectomies. Our cohort consisted of 52 ccRCC and 14 pRCC patients, of whom 50 were male (%76) and 16 were female (%24). Among the 52 ccRCC patients, 18 had both cortico-medullary phase contrast-enhanced CT and MRI, 15 had only cortico-medullary phase CT and 19 had only MRI examination. In the pRCC group, 8 patients had both cortico-medullary phase contrast-enhanced CT and MRI, 3 had only cortico-medullary phase CT and 3 had only MRI. We both calculated mean tumor attenuation values on cortico-medullary phase MDCT images as HU (hounsfield unit) and also tumor mean signal intensity values on FSE T2 weighted MR images, using both region of interest and whole lesion measurements including normal renal cortex. The obtained values were compared with the grading results of the ccRCC and pRCC tumors according to the WHO/International Society of Urological Pathology grading system.
RESULTS: A significant positive correlation was found between the mean attenuation values of both tumor subtypes on cortico-medullary phase contrast-enhanced CT and their grades (p < 0.001). High grade tumors exhibited higher mean attenuation values (74.3 ± 22.3 HU) than the low grade tumors (55.2 ± 23.7 HU) in both subtypes. However, a statistically significant correlation was not found between the mean signal intensity values of the two tumor subtypes on FSE T2 weighted MR images and their grades (p > 0.05). Low grade tumors had a mean signal intensity value of 408.9 ± 44.6, while high grade tumors showed a value of 382.1 ± 44.2. The analysis of the ccRCC group patients, yielded a statistically significant correlation between the mean signal intensity values on T2 weighted images and tumor grading (p < 0.001). Low grade (grade 1-2) ccRCC patients exhibited higher mean signal intensity values (475.7 ± 51.3), as compared to those of high grade (grade 3-4) (418.5 ± 45.7) tumors. On the other hand, analysis of the pRCC group patients revealed that there was a significant correlation between the mean attenuation values of tumors on cortico-medullary phase contrast-enhanced CT and their grades (p < 0.001). High grade papillary subtype tumors (54.2 ± 25.2) showed higher mean attenuation values than the low grade (35.5 ± 18.8) ones.
CONCLUSIONS: Contrast-enhanced MDCT and T2 weighted FSE MRI can play a considerable role in the discrimination of low grade versus high grade tumors of both subtype RCC patients. Thus, these non-invasive evaluation techniques may have positive impact on the determination of the management and treatment strategies of these patients.
引用
- Halefoglu AM, Ozagari AA. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon. Radiol Med. 2021. PMID: 34100169. doi:10.1007/s11547-021-01350-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。